Impact of oral hygiene on febrile neutropenia during breast cancer chemotherapy.
Breast cancer
Chemotherapy
Febrile neutropenia
Oral bacteria count
Oral hygiene
Journal
Breast cancer (Tokyo, Japan)
ISSN: 1880-4233
Titre abrégé: Breast Cancer
Pays: Japan
ID NLM: 100888201
Informations de publication
Date de publication:
Jan 2023
Jan 2023
Historique:
received:
21
07
2022
accepted:
16
10
2022
pubmed:
23
10
2022
medline:
7
1
2023
entrez:
21
10
2022
Statut:
ppublish
Résumé
Oral hygiene is crucial in the management of oral and febrile complications during chemotherapy for cancer. This study aimed to investigate the impact of oral hygiene on the incidence of febrile neutropenia (FN) throughout the course of chemotherapy for breast cancer. A total of 137 patients with breast cancer who underwent four cycles of adjuvant chemotherapy with docetaxel and cyclophosphamide (TC) combination therapy or docetaxel alone were assessed for oral hygiene by quantifying the number of oral bacteria they harbored. These patients received professional oral health care (POHC). Eighteen patients underwent primary prophylaxis with granulocyte colony-stimulating factors. The relationship between oral bacteria count and FN incidence was retrospectively assessed. The FN incidence rate was 47.4% throughout all treatment cycles (32.8%, 13.5%, 14.3%, and 14.4% in cycles 1, 2, 3, and 4, respectively). The oral bacteria count decreased with each treatment cycle (cycle 1: 9.10 × 10 FN incidence decreased with each treatment cycle and was associated with changes in oral bacteria counts. The oral bacterial count was one of risk factors for FN development in breast cancer.
Identifiants
pubmed: 36271187
doi: 10.1007/s12282-022-01410-9
pii: 10.1007/s12282-022-01410-9
doi:
Substances chimiques
Docetaxel
15H5577CQD
Granulocyte Colony-Stimulating Factor
143011-72-7
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
151-155Informations de copyright
© 2022. The Author(s), under exclusive licence to The Japanese Breast Cancer Society.
Références
Kuderer NM, Dale DC, Crawford J, Cosler LE, Lyman GH. Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. Cancer. 2006;106:2258–66. https://doi.org/10.1002/cncr.21847 .
doi: 10.1002/cncr.21847
Aapro MS, Bohlius J, Cameron DA, Dal Lago L, Donnelly JP, Kearney N, et al. 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. Eur J Cancer. 2011;47:8–32. https://doi.org/10.1016/j.ejca.2010.10.013 .
doi: 10.1016/j.ejca.2010.10.013
National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology. Hematopoietic Growth Factors (Version 1.2022). 2022. https://www.nccn.org/professionals/physician_gls/pdf/growthfactors.pdf . Accessed February 20, 2022.
Zecha JAEM, Raber-Durlacher JE, Laheij AMGA, Westermann AM, Epstein JB, De Lange J, et al. The impact of the oral cavity in febrile neutropenia and infectious complications in patients treated with myelosuppressive chemotherapy. Support Care Cancer. 2019;27:3667–79. https://doi.org/10.1007/s00520-019-04925-8 .
doi: 10.1007/s00520-019-04925-8
Papapanou PN. Systemic effects of periodontitis: lessons learned from research on atherosclerotic vascular disease and adverse pregnancy outcomes. Int Dent J. 2015;65:283–91. https://doi.org/10.1111/idj.12185 .
doi: 10.1111/idj.12185
Blijlevens NMA, Logan RM, Netea MG. Mucositis: from febrile neutropenia to febrile mucositis. J Antimicrob Chemother. 2009;63:i36–40. https://doi.org/10.1093/jac/dkp081 .
doi: 10.1093/jac/dkp081
Van Der Velden WJFM, Blijlevens NMA, Feuth T, Donnelly JP. Febrile mucositis in haematopoietic SCT recipients. Bone Marrow Transpl. 2009;43:55–60. https://doi.org/10.1038/bmt.2008.270 .
doi: 10.1038/bmt.2008.270
Soga Y, Yamasuji Y, Kudo C, Matsuura-Yoshimoto K, Yamabe K, Sugiura Y, et al. Febrile neutropenia and periodontitis: lessons from a case periodontal treatment in the intervals between chemotherapy cycles for leukemia reduced febrile neutropenia. Support Care Cancer. 2009;17:581–7. https://doi.org/10.1007/s00520-008-0532-z .
doi: 10.1007/s00520-008-0532-z
Cullen M, Steven N, Billingham L, Gaunt C, Hastings M, Simmonds P, et al. Antibacterial prophylaxis after chemotherapy for solid tumors and lymphomas. N Engl J Med. 2005;353:988–98. https://doi.org/10.1056/nejmoa050078 .
doi: 10.1056/nejmoa050078
Kashiwazaki H, Matsushita T, Sugita J, Shigematsu A, Kasashi K, Yamazaki Y, et al. Professional oral health care reduces oral mucositis and febrile neutropenia in patients treated with allogeneic bone marrow transplantation. Support Care Cancer. 2012;20:367–73. https://doi.org/10.1007/s00520-011-1116-x .
doi: 10.1007/s00520-011-1116-x
Nishizawa T, Niikura Y, Akasaka K, Watanabe M, Kurai D, Amano M, et al. Pilot study for risk assessment of aspiration pneumonia based on oral bacteria levels and serum biomarkers. BMC Infect Dis. 2019; 19. https://doi.org/10.1186/s12879-019-4327-2 .
Kosaka Y, Rai Y, Masuda N, Takano T, Saeki T, Nakamura S, et al. Phase III placebo-controlled, double-blind, randomized trial of pegfilgrastim to reduce the risk of febrile neutropenia in breast cancer patients receiving docetaxel/cyclophosphamide chemotherapy. Support Care Cancer. 2015;23:1137–43. https://doi.org/10.1007/s00520-014-2597-1 .
doi: 10.1007/s00520-014-2597-1
Kanda Y. Investigation of the freely available easy-to-use software “EZR” for medical statistics. Bone Marrow Transpl. 2013;48:452–8. https://doi.org/10.1038/bmt.2012.244 .
doi: 10.1038/bmt.2012.244
Kilian M, Chapple ILC, Hannig M, Marsh PD, Meuric V, Pedersen AML, et al. The oral microbiome—an update for oral healthcare professionals. Br Dent J. 2016;221:657–66. https://doi.org/10.1038/sj.bdj.2016.865 .
doi: 10.1038/sj.bdj.2016.865
Galloway-Peña JR, Smith DP, Sahasrabhojane P, Ajami NJ, Wadsworth WD, Daver NG, et al. The role of the gastrointestinal microbiome in infectious complications during induction chemotherapy for acute myeloid leukemia. Cancer. 2016;122:2186–96. https://doi.org/10.1002/cncr.30039 .
doi: 10.1002/cncr.30039
Jensen SB, Mouridsen HT, Reibel J, Brünner N, Nauntofte B. Adjuvant chemotherapy in breast cancer patients induces temporary salivary gland hypofunction. Oral Oncol. 2008;44:162–73. https://doi.org/10.1016/j.oraloncology.2007.01.015 .
doi: 10.1016/j.oraloncology.2007.01.015
Epstein JB, Tsang AHF, Warkentin D, Ship JA. The role of salivary function in modulating chemotherapy-induced oropharyngeal mucositis: a review of the literature. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2002;94:39–44. https://doi.org/10.1067/moe.2002.126018 .
doi: 10.1067/moe.2002.126018
Haverman TM, Raber-Durlacher JE, Rademacher WMH, Vokurka S, Epstein JB, Huisman C, et al. Oral complications in hematopoietic stem cell recipients: the role of inflammation. Mediators Inflamm. 2014;2014:1–18. https://doi.org/10.1155/2014/378281 .
doi: 10.1155/2014/378281
Wong HM. Oral complications and management strategies for patients undergoing cancer therapy. Sci World J. 2014;2014:1–14. https://doi.org/10.1155/2014/581795 .
doi: 10.1155/2014/581795
Coullioud D, Van Der Auwera P, Viot M, Lasset C. Prospective multicentric study of the etiology of 1051 bacteremic episodes in 782 cancer patients. Support Care Cancer. 1993;1:34–46. https://doi.org/10.1007/bf00326637 .
doi: 10.1007/bf00326637
Elad S, Cheng KKF, Lalla RV, Yarom N, Hong C, Logan RM, et al. MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy. Cancer. 2020;126:4423–31. https://doi.org/10.1002/cncr.33100 .
doi: 10.1002/cncr.33100
Musha A, Hirai C, Kitada Y, Tsunoda A, Shimada H, Kubo N, et al. Relationship between oral mucositis and the oral bacterial count in patients with head and neck cancer undergoing carbon ion radiotherapy: A prospective study. Radiother Oncol. 2022;167:65–71. https://doi.org/10.1016/j.radonc.2021.12.010 .
doi: 10.1016/j.radonc.2021.12.010
Mizuno H, Mizutani S, Ekuni D, Tabata-Taniguchi A, Maruyama T, Yokoi A, et al. New oral hygiene care regimen reduces postoperative oral bacteria count and number of days with elevated fever in ICU patients with esophageal cancer. J Oral Sci. 2018;60:536–43. https://doi.org/10.2334/josnusd.17-0381 .
doi: 10.2334/josnusd.17-0381
Ishikawa T, Sakamaki K, Narui K, Nishimura H, Sangai T, Tamaki K, et al. Prospective cohort study of febrile neutropenia in breast cancer patients administered with neoadjuvant and adjuvant chemotherapies: CSPOR-BC FN study. Breast. 2021;56:70–7. https://doi.org/10.1016/j.breast.2021.01.005 .
doi: 10.1016/j.breast.2021.01.005
Kimura Y, Sasada S, Emi A, Masumoto N, Kadoya T, Okada M. Febrile neutropenia and role of prophylactic granulocyte colony-stimulating factor in docetaxel and cyclophosphamide chemotherapy for breast cancer. Support Care Cancer. 2021;29:3507–12. https://doi.org/10.1007/s00520-020-05868-1 .
doi: 10.1007/s00520-020-05868-1